Elanco Animal Health says expanding parasite and allergy seasons, combined with demand for newer products, are supporting growth across its U.S. and international pet health businesses. The company reaffirmed expectations for high-single-digit to low-double-digit U.S. Pet Health growth in the second half of 2026.
Elanco Animal Health reported second-quarter 2026 revenue of $1.368 billion, up 10% year over year, and raised its full-year financial guidance following growth across its Pet Health and Farm Animal businesses.
Elanco’s 2025 Impact Report outlines the company’s progress in advancing animal health through product innovation, sustainable food production, veterinary support and community investment while reinforcing its long-term business strategy.
Newly published research in Parasites & Vectors found that Elanco’s Credelio Quattro demonstrated a faster speed of kill against black-legged ticks than Simparica Trio and NexGard Plus, while maintaining efficacy throughout the monthly dosing interval. The company said the findings support the role of rapid tick control in reducing the risk of tick-borne disease transmission in dogs.
Elanco Animal Health plans to launch Elanco Ventures, a corporate venture capital platform backed by a $25 million multi-year commitment to support early-stage innovation in animal health, technology and One Health.
New World screwworm has officially reached U.S. livestock, prompting Elanco Animal Health to activate a portfolio of treatment and prevention tools for producers, veterinarians and pet owners. As the parasite resurfaces north of the Florida Keys for the first time in more than 50 years, the company says it is working alongside federal agencies and industry partners to help contain its spread and minimize the impact on animal health, welfare and producer livelihoods. Additional information and response resources are available through USDA, FDA and Elanco’s New World screwworm information updates.
Elanco has launched Befrena™, a new anti-IL-31 monoclonal antibody injection for canine allergic and atopic dermatitis that provides itch relief within 24 hours and lasts up to eight weeks.
Elanco Animal Health reported double-digit revenue growth in the first quarter of 2026, driven by strong performance from companion animal products including Credelio Quattro and Zenrelia. The company also raised its full-year revenue, EBITDA and EPS guidance while improving its leverage outlook.
Elanco Animal Health will report its first quarter 2026 financial results on May 6, followed by a live webcast and conference call with investors and media.
Elanco reported continued underlying revenue growth in 2025 and outlined 2026 guidance calling for mid-single-digit organic revenue gains and higher profit growth as innovation scales.
Sign up for free to receive the latest veterinary news, product announcements, and industry developments.